Evidence map›Paper›PMID 32728970›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.

S Comas, E Luguera, J Molero, C Balaña, A Estival, S Castañer, C Carrato, C Hostalot, P Teixidor, S Villà

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Anatomical-molecular interaction in glioblastoma: subventricular zone involvement and MGMT-related survival benefit.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Glioblastoma and Methionine Addiction.International journal of molecular sciences · 2022
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S ComasRadiation Oncology, Institut Català D'Oncologia, c/ del Canyet SN, 08916, Badalona, Catalonia, Spain.
E LugueraPhysics, Institut Català D'Oncologia, Badalona, Catalonia, Spain.
J MoleroPhysics, Institut Català D'Oncologia, Badalona, Catalonia, Spain.
C BalañaMedical Oncology, Institut Català D'Oncologia, Badalona, Catalonia, Spain.
A EstivalMedical Oncology, Institut Català D'Oncologia, Badalona, Catalonia, Spain.
S CastañerNeuroradiology, Institut de Diagnòstic Per La Imatge, Badalona, Catalonia, Spain.
C CarratoPathology. Hospital Universitari Germans Trias I Pujol, Badalona, Catalonia, Spain.
C HostalotNeurosurgery. Hospital Universitari Germans Trias I Pujol, Badalona, Catalonia, Spain.
P TeixidorNeurosurgery. Hospital Universitari Germans Trias I Pujol, Badalona, Catalonia, Spain.
S VillàRadiation Oncology, Institut Català D'Oncologia, c/ del Canyet SN, 08916, Badalona, Catalonia, Spain. svilla@iconcologia.net.ORCID http://orcid.org/0000-0002-9089-4807

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is growing evidence that the subventricular zone (SVZ) may be involved in both the initiation and progression of glioblastoma (GB). We aimed to assess tumor proximity to the SVZ as a potential prognostic factor in GB.

methodRetrospective study of 133 patients diagnosed with primary GB who underwent surgery followed by temozolomide-based chemoradiation between 2010 and 2016. All lesions were classified according to their anatomic relation with the SVZ. We determined the effect of tumor contact with the SVZ on progression-free survival (PFS), overall survival (OS), type, and patterns of recurrence.

resultsAt a median follow-up of 18.6 months (95% CI 15.9-21.2), PFS and OS were 7.5 (95% CI 6.7-8.3) and 13.9 (95% CI 10.9-16.9) months, respectively. On the univariate analyses, initial contact with the SVZ was a factor for poor prognosis for both PFS (6.1 vs. 8.7 months; p = 0.006) and OS (10.6 vs. 17.9 months; p = 0.037). On the multivariate analysis, tumor contact with the SVZ remained statistically significant for PFS, but not OS. Patients with SVZ-contacting tumors presented a higher rate of aggressive clinical progression (30.9% vs. 11.3%; p = 0.007) and contralateral relapse patterns (23.4% vs. 9.1%; p = 0.048).

conclusionsOur results suggest that glioblastoma contact with the SVZ appears to be an independent prognostic factor for poor PFS. The presence of an SVZ-contacting tumor was associated with more aggressive recurrences and a higher rate of contralateral relapses. These findings suggest that this variable may be a new prognostic factor in glioblastoma.

Indexed as

Neoplasm Recurrence, LocalAntineoplastic Agents, AlkylatingBrain NeoplasmsChemoradiotherapyConfidence IntervalsFemaleFollow-Up StudiesGlioblastomaHumansLateral VentriclesMagnetic Resonance ImagingMalePrognosisProgression-Free SurvivalRadiotherapy DosageRetrospective StudiesAntineoplastic Agents, AlkylatingTemozolomideCancer stem cellGlioblastomaPrognostic factorSubventricular zoneTumor location

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.